This is the publisher’s final pdf. The published article is copyrighted by the American Society for Biochemistry and Molecular Biology and can be found at: http://www.jlr.org/content/56/10/1936This research was originally published in the Journal of Lipid Research. Lytle, K. A., Depner, C. M., Wong, C. P., & Jump, D. B. Docosahexaenoic acid attenuates Western diet-induced hepatic fibrosis in Ldlr−/− mice by targeting the TGFβ-Smad3 pathway. Journal of Lipid Research. 2015. 56:1936-1946. © the American Society for Biochemistry and Molecular BiologyAccess to this item has been restricted by repository administrators at the request of the publisher until August 27, 2016.DHA (22:6,ω3), but not EPA (20:5,ω3), attenuates Western diet (WD)-induced...
Liver-specific ablation of cytochrome P450 reductase in mice (LCN) results in hepatic steatosis that...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Hepatic steatosis, an early stage of non-alcoholic fatty liver disease, is commonly present in obesi...
<div><p>Background</p><p>Nonalcoholic fatty liver disease (NAFLD) is a major public health concern i...
<div><p>Background</p><p>Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic f...
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease and a ...
This is an author's peer-reviewed final manuscript, as accepted by the publisher. The article is cop...
Background: Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver di...
Regulating dietary fat absorption may impact progression of nonalcoholic fatty liver disease (NAFLD)...
Non-alcoholic steatohepatitis (NASH), defined as excess hepatic lipid and chronic inflammation, prov...
© 2017 The Author(s). Background: Eicosapentaenoic acid (EPA, C20:5n-3), docosahexaenoic acid (DHA, ...
Background Nonalcoholic fatty liver disease (NAFLD) is a major public health burden in western socie...
<div><p>Background</p><p>Nonalcoholic fatty liver disease (<b>NAFLD</b>) is a major public health bu...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Liver-specific ablation of cytochrome P450 reductase in mice (LCN) results in hepatic steatosis that...
Liver-specific ablation of cytochrome P450 reductase in mice (LCN) results in hepatic steatosis that...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Hepatic steatosis, an early stage of non-alcoholic fatty liver disease, is commonly present in obesi...
<div><p>Background</p><p>Nonalcoholic fatty liver disease (NAFLD) is a major public health concern i...
<div><p>Background</p><p>Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic f...
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease and a ...
This is an author's peer-reviewed final manuscript, as accepted by the publisher. The article is cop...
Background: Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver di...
Regulating dietary fat absorption may impact progression of nonalcoholic fatty liver disease (NAFLD)...
Non-alcoholic steatohepatitis (NASH), defined as excess hepatic lipid and chronic inflammation, prov...
© 2017 The Author(s). Background: Eicosapentaenoic acid (EPA, C20:5n-3), docosahexaenoic acid (DHA, ...
Background Nonalcoholic fatty liver disease (NAFLD) is a major public health burden in western socie...
<div><p>Background</p><p>Nonalcoholic fatty liver disease (<b>NAFLD</b>) is a major public health bu...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Liver-specific ablation of cytochrome P450 reductase in mice (LCN) results in hepatic steatosis that...
Liver-specific ablation of cytochrome P450 reductase in mice (LCN) results in hepatic steatosis that...
Background & Aims: Non-alcoholic fatty liver disease accompanies obesity and is independently associ...
Hepatic steatosis, an early stage of non-alcoholic fatty liver disease, is commonly present in obesi...